1. Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients
- Author
-
Franziska Büscheck, Mariam Sulimankhil, Nathaniel Melling, Doris Höflmayer, Claudia Hube‐Magg, Ronald Simon, Cosima Göbel, Andrea Hinsch, Sören Weidemann, Jacob R. Izbicki, Frank Jacobsen, Tim Mandelkow, Niclas C. Blessin, Christina Möller‐Koop, Florian Lutz, Florian Viehweger, Katharina Möller, Guido Sauter, Maximilian Lennartz, Eike Burandt, Patrick Lebok, Sarah Minner, Sarah Bonk, Hartwig Huland, Markus Graefen, Thorsten Schlomm, and Christoph Fraune
- Subjects
BIRC5 ,deletion ,ERG ,prostate cancer ,Survivin ,TMA ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Survivin is an inhibitor of apoptosis. Aberrant survivin expression occurs in malignant tumors and has often been linked to unfavorable patient outcome. Here we analyzed 12 432 prostate cancers by immunohistochemistry. Survivin immunostaining was regularly expressed at high levels in normal prostate epithelium but expression was often reduced in prostate cancers. Among 9492 evaluable prostate cancers, 9% expressed survivin strongly, 19% moderately, 28% weakly, and 44% lacked it. Loss of cytoplasmic survivin was seen in advanced tumor stage, higher Gleason score, preoperative PSA levels, and Ki‐67 labeling index, and associated with earlier PSA recurrence (P
- Published
- 2020
- Full Text
- View/download PDF